Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Virion Maturation and Assembly

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multimodal MRI reveals microstructural and macrostructural alterations in Parkinson's disease: A combined 3D structural and NODDI study.

Magnetic resonance imaging·2026

Same author

AbCVista: a deep learning framework for predicting antibody conformational ensembles.

Protein & cell·2026

Same author

Lithium-Rich Antifluorite Li<sub>5</sub>Fe<i><sub>x</sub></i>Al<sub>1-<i>x</i></sub>O<sub>4</sub>: Phase-Controllable Syntheses, Local Structural Evolution, and Electrochemical Performance.

Inorganic chemistry·2026

Same author

Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation.

ACS infectious diseases·2026

Same author

Pomelo-derived exosomes suppress vesicular stomatitis virus infection through GSK3β dependent regulation of innate immune signaling.

Food & function·2026

Same author

Coating-Integrated Joule Heating Architecture for Energy-Efficient Hydrogen Release from Chemical Carriers.

Journal of the American Chemical Society·2026

Same journal

Favipiravir Is Associated With Reduced 28-Day Mortality in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Propensity Score-Matched Study.

Journal of medical virology·2026

Same journal

Defining Mechanistic Parameters for Covalent CD4-Based CAR-T Cells in HIV Reservoir Control.

Journal of medical virology·2026

Same journal

Development and Application of a Quadruplex TaqMan-MGB qPCR Assay for Simultaneous Detection of Important Mosquito-Borne Orthoflaviviruses.

Journal of medical virology·2026

Same journal

sVCAM-1 and Hematological Profiles Are Associated With CD4-Defined Disease Status in HIV Infection.

Journal of medical virology·2026

Same journal

An Explainable Machine Learning Model for Early Prediction of Incident Myocardial Injury in Patients With Severe Fever With Thrombocytopenia Syndrome.

Journal of medical virology·2026

Same journal

Global Performance of Human Papillomavirus Typing, Screening, and Evaluation As Assessed Using Proficiency Panels Traceable to International Standards: A Retrospective Analysis, 2008-2024.

Journal of medical virology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Published on: September 7, 2010

TXD-198 Exhibits Inhibitory Activity Against SARS-CoV-2 by Upregulating ANO1.

Ruilin Chen¹, Weiya Kong¹, Chengyu Li¹

¹State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, P. R. China.

Journal of Medical Virology

|June 10, 2026

Summary

This summary is machine-generated.

TXD-198 shows potent antiviral activity against SARS-CoV-2, the virus causing COVID-19. This novel compound inhibits viral infection and inflammation, offering a promising therapeutic candidate for future treatments.

Keywords:

SARS‐CoV‐2 antiviral drugs drug screening spike

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 11, 2026

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Published on: September 7, 2010

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses

Published on: February 27, 2026

Area of Science:

Virology
Pharmacology
Immunology

Background:

The global health crisis caused by SARS-CoV-2 necessitates the development of effective antiviral treatments.
Existing therapies face challenges, highlighting the need for novel therapeutic agents.

Purpose of the Study:

To identify and characterize novel antiviral compounds against SARS-CoV-2.
To investigate the mechanism of action of TXD-198 in inhibiting SARS-CoV-2 infection.

Main Methods:

Utilized a transcription- and replication-competent virus-like particle (trVLP) system to assess TXD-198's antiviral activity.
Validated findings using replication-competent rVSV-Venus-VSV∆G-SARS2-S∆21 and SARS-CoV-2 spike-pseudotyped lentiviral systems (PSVs).
Conducted transcriptomic analysis to elucidate the molecular mechanisms underlying TXD-198's effects.

Main Results:

TXD-198 demonstrated potent inhibition of SARS-CoV-2 with an IC50 of 1.04 μM and a high selectivity index of 42.55.
TXD-198 exhibited dual antiviral action, including direct viral inhibition and anti-inflammatory effects.
Upregulation of the ANO1 gene was identified as a key component of TXD-198's antiviral mechanism, with ANO1 knockdown reversing its efficacy.

Conclusions:

TXD-198 is a potent inhibitor of SARS-CoV-2 infection with a favorable safety profile.
The compound's dual mechanism involving direct viral inhibition and modulation of ANO1 expression presents a novel therapeutic strategy.
TXD-198 warrants further clinical investigation as a potential treatment for COVID-19.